



No. JSPCS-22/022

Date 16 December 2022

Re: Notification of the commercial operation of new production line - conventional medicine  
To: Director and manager, The Stock Exchange of Thailand

JSP Pharmaceutical Manufacturing (Thailand) PCL. ("the Company") had reported in prospectus in relation to objectives of utilisation of the proceeds received from Initial Public Offering of the capital increase ordinary shares. Subsequently, the Company has been approved by the Extraordinary Shareholders Meeting No. 1/2565 to change the objectives since 16 August 2022. Whereby, one of the objectives is improvement and expansion of factory at Bangkok.

The Company would like to inform the Stock Exchange of Thailand that expansion of convention medicine production line at the Company's head office, Bangkok, has been completed and ready for commercial operation since 16 December 2022 onwards. This production line could support the production of conventional medicine approximately 20 - 25 million bottles annually.

Please be informed accordingly.

Sincerely yours,

JSP Pharmaceutical Manufacturing (Thailand) PCL.

Mr. Kriangkrai Rungruangthaweekul

Vice President of Finance

Investor Relations

Tel. 064 479 1691

Email [ir@jsppharma.com](mailto:ir@jsppharma.com)

บริษัท โรงงานเภสัชอุตสาหกรรม เจเอสพี  
(ประเทศไทย) จำกัด (มหาชน)

255,257 ซอยสาธุประดิษฐ์ 58 แขวงบางโพงพาง  
เขตยานนาวา กรุงเทพมหานคร 10120  
โทรศัพท์ (Tel.) +66(2) 284-1218  
โทรสาร (Fax) +66(2) 294-0705

JSP PHARMACEUTICAL MANUFACTURING  
(THAILAND) PUBLIC COMPANY LIMITED

255,257 Soi Sathupradit 58 Bangpongpan,  
Yannawa Bangkok 10120  
Email : [contact@jsppharma.com](mailto:contact@jsppharma.com)  
Website : [www.jsppharma.com](http://www.jsppharma.com)